EU Priority Medicines Scheme: Early Eligibility, Regular Advice, And A Bonus For SMEs
This article was originally published in SRA
Executive Summary
The European Medicines Agency has confirmed that its proposed priority medicines initiative, PRIME, will be targeted at those new medicines that fulfil the current criteria for accelerated assessment – ie, those that could benefit patients who have no treatment options or that represent a major therapeutic advantage over existing products.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.